Should a CRO's qualification strategy differ based on whether the company is growing organically vs. chasing growth through M&A or heavy upmarket expansion?

Yes — dramatically. A CRO's qualification strategy must be rebuilt, not just adjusted, when the growth motion shifts. Organic growth rewards high-velocity, repeatable qualification against a known ICP. M&A and upmarket expansion introduce new personas, unknown buying processes, and displacement selling — requiring depth-first frameworks instead.

---

THE DETAIL

Organic Growth → Precision at Volume

In an organic, product-led-or-inbound motion, your ICP is proven. The job is to replicate what already works. Here, a tiered approach wins:

1. BANT (or SPICE) at the top of funnel — fast triage for SDRs. BANT remains the SMB standard for short cycles under 60 days.
2. MEDDIC at mid-funnel — deals above $50K ACV need champion mapping and metrics. 73% of SaaS companies exceeding $100K ARR use MEDDIC or a variant.
3. Disqualification speed is the KPI. Pipeline hygiene > pipeline volume.

Key organic levers: ICP fit scoring (Salesforce/HubSpot + Clay enrichment), high-volume call review via Gong or Chorus, and rep coaching against repeatable discovery scripts.

---

M&A / Upmarket Expansion → Depth-First, Deal-by-Deal

When you're chasing enterprise logos, displacing incumbents post-acquisition, or entering new buyer personas, volume-based qualification actively destroys value. The framework must shift:

1. Full MEDDPICC is non-negotiable. MEDDPICC is designed for deals with multiple stakeholders, long sales cycles, procurement complexity, and competitive evaluations. The Paper Process (P) and Competition (C) legs of the framework — the two additions beyond MEDDIC — are specifically where upmarket deals die. Its eight elements cover the primary reasons enterprise deals are lost — including paper process delays and champion turnover.
2. Economic Buyer access is gate-locked. You don't advance a stage without confirmed EB contact. For enterprise deals, omitting Economic Buyer mapping leaves critical qualification gaps that surface at close.
3. Evidence standards, not checkbox completion. Organizations that enforce MEDDPICC with evidence standards — not just field completion — see 31% fewer late-stage deal losses.
4. M&A integration = dual-ICP complexity. When your product set just expanded via acquisition, your reps are now selling into unfamiliar buyer personas. Instead of entering a new market organically, companies often acquire an established local player to fast-track access to a new geography or customer segment. Your qualification criteria must account for the *acquired* customer base's buying behavior — not just your legacy ICP.

---

The Benchmark Decision Table

Some organizations implement a tiered approach, using MEDDIC for smaller or less complex deals and MEDDPICC for strategic enterprise opportunities where the additional qualification depth is justified.

---

Cross-Functional Implication

The CRO's job isn't just picking the framework — it's standardizing language across the entire GTM. In many organizations, SDRs might leverage BANT, AEs might apply MEDDIC, and Marketing might adopt another approach entirely — resulting in a fragmented and uncoordinated GTM motion. In M&A scenarios, this fragmentation compounds because you've now merged two separate sales cultures.

---